Caley Castelein
CIK 1355758 · last filed 2026-06-15
Caley Castelein is a corporate insider who has filed 46 SEC Form 4 insider transactions across 5 companies since 2016. The most recent filing, for WHWK, was dated Jun 15, 2026. Across all open-market trades the lifetime net is +$7.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $10.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$10.92M
5
46
$7.12M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WHWK | Director | 2,440,794 | $4.47 | $10.92M | $0 | 3 | 2026-06-15 |
| Tourmaline Bio, Inc. (TRML) Delisted | Director | 0 | $47.98 | $0 | $280.6K | 5 | 2025-10-28 |
| Whitehawk Therapeutics, Inc. (AADI) Delisted | Director | 2,185,692 | $2.05 | $4.48M | $3.40M | 6 | 2025-03-04 |
| ViewRay, Inc. (VRAY) Delisted | Director | 99,047 | $0.03 | $2.5K | $3.44M | 20 | 2023-07-21 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | Director | 19,694 | $33.00 | $649.9K | $0 | 6 | 2021-07-02 |
Recent Filings
46 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-15 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | WHWK | Grant (A) | +255,102 | $1000.0K | EDGAR |
| 2025-10-28 | Tourmaline Bio, Inc. (TRML) Delisted | Mixed | −947,936 | $0 | EDGAR |
| 2025-10-17 | Tourmaline Bio, Inc. (TRML) Delisted | Gift (G) | −522 | $0 | EDGAR |
| 2025-06-16 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | Tourmaline Bio, Inc. (TRML) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-04 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | +1,666,000 | $4.00M | EDGAR |
| 2024-06-14 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | Tourmaline Bio, Inc. (TRML) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-10-27 | Tourmaline Bio, Inc. (TRML) Delisted | Buy (P) | +20,000 | $280.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.